The International Classification of Headache Disorders, 2nd Edition (ICHD-II)—-Revision of Criteria for 8.2<i>Medication-Overuse Headache</i>

Silberstein, SD; Olesen, Jes; Bousser, M.-G.; Hc, Diener; Dodick, David W.; First, Michael B.; Goadsby, PJ; Göbel, Hartmut; Lainez, M. J. A.; Jw, Lance; Lipton, RB; Nappi, Giuseppe; Sakai, Fumihiko; Schoenen, J; Steiner, TJ

doi:10.1111/j.1468-2982.2005.00878.x

Cited by 383 publications

(247 citation statements)

References 75 publications

Supporting

Mentioning

247

Contrasting

Order By: Relevance

“…All patients overused acute medications. Patients also fit Silberstein and Lipton's 1996 transformed migraine diagnostic criteria [14,15]. Patients presented either anticipatory anxiety, fearing a headache attack during a pain-free period, or fearing that pain would worsen during a period of mild headache.…”

Section: Resultsmentioning

confidence: 99%

Cephalalgiaphobia: a possible specific phobia of illness

et al. 2007

View full text Add to dashboard Cite

Psychiatric comorbidity, mainly anxiety and depression, are common in chronic migraine (CM). Phobias are reported by half of CM patients. Phobic avoidance associated with fear of headache or migraine attack has never been adequately described. We describe 12 migraine patients with particular phobic-avoidant behaviours related to their headache attacks, which we classified as a specific illness phobia, coined as cephalalgiaphobia. All patients were women, mean age 42, and all had a migraine diagnosis (11 CM, all overused acute medications). Patients had either a phobia of a headache attack during a pain-free state or a phobia of pain worsening during mild headache episodes. Patients overused acute medication as phobic avoidance. It is a significant problem, associated with distress and impairment, interfering with medical care.Cephalalgiaphobia is a possible specific phobia of illness, possibly linked to progression of migraine to CM and to acute medication overuse headache.

show abstract

Section: Resultsmentioning

confidence: 99%

Cephalalgiaphobia: a possible specific phobia of illness

et al. 2007

View full text Add to dashboard Cite

show abstract

“…The International Classification of Headache Disorders, 2nd edition (ICHD-2) [2] and its appendix version [3] first adopted the following CDH subtypes: chronic migraine (CM), chronic tension-type headache (CTTH), new dailypersistent headache (NDPH) and hemicrania continua (HC). Many patients with CDH also have medicationoveruse headache [4,5]. Although the source of pain in primary CDH is unknown and may be dependent on the subtype, research findings suggest that the following mechanisms, alone or in combination, contribute to the process [6]: (1) abnormal excitation of peripheral nociceptive afferent fibers in the meninges; (2) enhanced responsiveness of trigeminal nucleus caudalis neurons; (3) decreased pain modulation from higher centers such as the periaqueductal gray matter; (4) spontaneous central pain generated by activation of the ''on cells'' in the medulla; (5) decreased serotonin levels; and (6) central sensitization.…”

Section: Introductionmentioning

confidence: 99%

The outcomes for nasal contact point surgeries in patients with unsatisfactory response to chronic daily headache medications

Abu-Samra

Gawad

Agha

2011

Eur Arch Otorhinolaryngol

View full text Add to dashboard Cite

The nasal contact point may act as a trigger point or peripheral enhancer in patients with chronic daily headaches. A total of 42 patients had unsatisfactory response to medical treatment for chronic daily headache with radiologic evidence of nasal contact point. Of them, 12 (28.5%) patients were positive for the local anesthetic test. Those patients were operated upon to separate this contact by either septoplasties or submucous resections with or without partial turbinectomies. The mean headache frequency was reduced from 22 to 7 days/month. The mean headache severity was reduced from 5.6 to 2.4. Eight (19%) patients became completely free from headache and its medications, six (75%) of them were positive for local anesthetic test. The patients were satisfied with postoperative monotherapy, or headache severity and frequency could be tolerated without medications in 26 (62%) patients. There was no improvement in seven (16.6%) patients and only one patient (2%) became worse. The overall satisfaction was 83 and 81% for positive and negative anesthetic tests, respectively. The average monthly medication cost was reduced from $85 to 32. Nasal contact point surgery for chronic daily headache patients can satisfy them compared to previously unsatisfactory medications. Nasal contact point may contribute to potentiating or triggering chronic daily headache.

show abstract

“…Criteria for chronic migraine (Silberstein (16) and ICHD second edition (ICHD-II) revision (17)) were applied by all but four studies on chronic migraine (75%). Migraine cases were not always deemed representative for the diagnosed migraine type because lumbar punctures were performed to exclude other neurologic diseases (five studies), migraine patients were admitted to the hospital for unstated reasons (four studies) or because recruitment of cases was not clearly reported (11 studies) ( Table 1).…”

Section: Risk Of Bias Assessmentmentioning

confidence: 99%

Migraine biomarkers in cerebrospinal fluid: A systematic review and meta-analysis

et al. 2016

View full text Add to dashboard Cite

Objective: To perform a meta-analysis of migraine biomarkers in cerebrospinal fluid (CSF) and of corresponding blood concentrations. Methods: We conducted a systematic search for studies that measured biochemical compounds in CSF of chronic or episodic migraineurs and non-headache controls. Subsequent searches retrieved studies with blood measurements of selected CSF biomarkers. If a compound was assessed in three or more studies, results were pooled in a meta-analysis with standardised mean differences (SMD) as effect measures. Results: Sixty-two compounds were measured in 40 CSF studies. Most important results include: increased glutamate (five studies, SMD 2.22, 95% CI: 1.30, 3.13), calcitonin gene-related peptide (CGRP) (three studies, SMD: 3.80, 95% CI: 3.19, 4.41) and nerve growth factor (NGF) (three studies, SMD: 6.47, 95% CI: 5.55, 7.39) in chronic migraine patients and decreased b-endorphin (b-EP) in both chronic (four studies, SMD: -1.37, 95% CI: -1.80, -0.94) and interictal episodic migraine patients (three studies, SMD: -1.12, 95% CI: -1.65, -0.58). In blood, glutamate (interictal) and CGRP (chronic, interictal and ictal) were increased and b-EP (chronic, interictal and ictal) was decreased. Conclusions: Glutamate, b-EP, CGRP and NGF concentrations are altered in CSF and, except for NGF, also in blood of migraineurs. Future research should focus on the pathophysiological roles of these compounds in migraine.

show abstract

The International Classification of Headache Disorders, 2nd Edition (ICHD-II)—-Revision of Criteria for 8.2Medication-Overuse Headache

Abstract: The headache associated with medication overuse is variable and often has a peculiar pattern with characteristics shifting, even within the same day, from migraine-like to those of tension-type headache.

Cited by 383 publications

References 75 publications

Cephalalgiaphobia: a possible specific phobia of illness

Cephalalgiaphobia: a possible specific phobia of illness

The outcomes for nasal contact point surgeries in patients with unsatisfactory response to chronic daily headache medications

Migraine biomarkers in cerebrospinal fluid: A systematic review and meta-analysis

Contact Info

Product

Resources

About